Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.

Background: Fosgonimeton (ATH-1017) is being developed as a first-in-class regenerative therapy for people with Alzheimer's disease (AD) and dementia; potentially improving dementia symptoms and altering disease progression by reversing synaptic disconnection and neuronal loss.Objective: This random...

Full description

Bibliographic Details

Published in:	Journal of Alzheimer's Disease Vol. 86; no. 3; pp. 1399 - 1414
Main Authors:	Hua, Xue, Church, Kevin, Walker, William, L'Hostis, Philippe, Viardot, Geoffrey, Danjou, Philippe, Hendrix, Suzanne, Moebius, Hans J.
Format:	clinical trial research randomized controlled trial Journal Article
Published:	Sage Publications Inc. 2022
Online Access:	View this record in EBSCOhost